225AcDOTA-LM3

N/A

Report date: 2025/11/21 17:15:22

Base Information

Drug Name225AcDOTA-LM3

Drug Alias Name225AcDOTA-LM3

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug ConjugatesRadiation-emitting products > Nuclides > Actinium > 225Ac +[4]

Mechanisms of ActionSomatostatin receptor 2 antagonists

TargetsSomatostatin receptor 2

Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaN/A

Originator CompaniesCURANOSTICUM Wiesbaden-Frankfurt

China Registration ClassN/A

Develop Information

Active CompaniesCURANOSTICUM Wiesbaden-Frankfurt

Inactive CompaniesN/A

Active IndicationsPancreatic neuroendocrine tumors (pNET)

Inactive IndicationsN/A

Other Information

ATC CodeN/A